Hematologic Oncology

Orelabrutinib has been approved as a treatment option for patients with marginal zone lymphoma in Singapore.

Hematology experts highlight the MDS, lymphoma, and myeloma data they were most excited to see at the 2025 SOHO Annual Meeting.

A Yale study published identified the mechanism underlying the relationship between the development of AMKL and a specific genetic alteration that occurs.

Shira Dinner, MD, and Ibrahim Aldoss, MD, discuss key data in acute lymphoblastic leukemia presented at the 2025 EHA Congress.

Shira Dinner, MD, and Ibrahim Aldoss, MD, discuss data for subcutaneous in relapsed/refractory acute lymphoblastic leukemia.

The top 5 OncLive videos of the week cover insights in sarcoma, colorectal cancer, acute lymphoblastic leukemia, renal cell carcinoma.

A chemotherapy-free regimen of mosunetuzumab and polatuzumab vedotin improved PFS and response rates vs R-GemOx in relapsed/refractory LBCL.

Loncastuximab tesirine plus glofitamab demonstrated early promise in patients with relapsed or refractory large B-cell lymphoma.

Ghayas C. Issa, MD, MS, discusses the optimal timing of and approaches to genetic testing for NPM1 and KMT2A alterations in AML.

Frontline treatment with mosunetuzumab showed high antitumor activity in patients with marginal zone lymphoma regardless of risk status.

CER-1236 has received fast track designation from the FDA for the treatment of patients with acute myeloid leukemia.

The combination of ziftomenib and cytarabine/daunorubicin showed a manageable safety profile with early efficacy in NPM1-mutated and KMT2A-rearranged AML.

Favorable long-term outcomes were reported with brexu-cel in patients with B-ALL and low disease burden who achieved peak CAR T-cell expansion.

Findings from a meta-analysis associated asciminib with improved efficacy and safety vs other TKIs in chronic myeloid leukemia.

A post hoc analysis demonstrated the efficacy of olutasidenib monotherapy in primary refractory patients with IDH1-mutant AML.

Jorge Cortes, MD, discusses the state of the leukemia and lymphoma treatment paradigms in 2025 in recognition of Leukemia and Lymphoma Awareness Month

Ibrahim T. Aldoss, MD, discusses MRD negativity outcomes with ponatinib vs imatinib in newly diagnosed Philadelphia chromosome–positive ALL.

Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in August 2025.

Shira Dinner, MD, and Ibrahim Aldoss, MD, discuss the role of blinatumomab consolidation in BCR:ABL1–negative B-ALL.

Shira Dinner, MD, and Ibrahim Aldoss, MD, discuss the addition of blinatumomab to the CALGB 10403 regimen in MRD-negative acute lymphoblastic leukemia.

Rilzabrutinib has been approved by the FDA for persistent or chronic immune thrombocytopenia after an insufficient response to prior therapy.

Here is your guide to all therapeutic options that were cleared by the FDA in August 2025 spanning tumor types.

The European Medicines Agency has granted orphan drug designation to OXC-101 for the treatment of acute myeloid leukemia.

The EMA granted orphan designation to ADX-2191 for the management of LBCL of immune-privileged sites, including primary vitreoretinal lymphoma.

Julie M. Vose, MD, MBA, details the rationale for evaluating epcoritamab for the treatment of patients with relapsed/refractory DLBCL with limited options.